Dmg America LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.5Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
958clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Luxacore Z Dual $638K associated (2023-2025)
- Luxatemp Ultra $99K associated (2023-2025)
- Ecosite Elements $93K associated (2023-2025)
- Honigum $74K associated (2023-2025)
- Luxatemp $67K associated (2023-2025)
- Luxacrown $54K associated (2023-2025)
- Icon $44K associated (2023-2025)
- Luxaflow Ultra $30K associated (2023-2025)
- Honigum Pro $27K associated (2023-2025)
- Statusblue $23K associated (2023-2025)
- Tempocem Id $18K associated (2023-2025)
- Ecosite Bulk Fill $18K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Gary Radz | Denver, CO | General Practice (Dentist) | $434,377.95 |
| Joyce Bassett | Scottsdale, AZ | Dentist | $99,187.95 |
| Sarah Winter | Chino Hills, CA | General Practice (Dentist) | $76,507.27 |
| Ian Shuman | Pasadena, MD | Dentist | $45,993.50 |
| Todd Snyder | Laguna Niguel, CA | Dentist | $43,896.47 |
| Howard Glazer | Fort Lee, NJ | General Practice (Dentist) | $41,198.20 |
| Jack Ringer | Anaheim, CA | General Practice (Dentist) | $37,556.63 |
| Joel Berg | Seattle, WA | Pediatric Dentistry | $33,753.05 |
| Lee Brady | Glendale, AZ | Dentist | $32,454.70 |
| Jeffrey Lineberry | Bluffton, SC | General Practice (Dentist) | $27,376.76 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.